日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of maternal compensation on developmental phenotypes in a zebrafish model of severe congenital muscular dystrophy

母体补偿对斑马鱼严重先天性肌营养不良模型发育表型的影响

Flannery, Kyle P; Mowla, Shorbon; Battula, Namarata; Clark, L Rose; Oliveira, Callista D; Simhon, Lillian M; Liu, Deze; Venkatesan, Cynthia; Karas, Brittany F; Terez, Kristin R; Burbano, Daniel; Manzini, M Chiara

Morbidity and patient characteristics on acute presentation with sore throat: a multicentre national audit

咽喉痛急性发作时的发病率和患者特征:一项多中心全国性审计

Ton, T; Sheldon, A; Duncan, N; Gohil, R; Stewart, K; Sooby, P; Sproat, R; Hurley, R; To, K; Wilmont, V V; McMurran, L; Hey, S; Moen, C M; Corson, S; Clark, L; Douglas, C M

Foxi2 and Sox3 are master transcription regulators that control ectoderm germ layer specification in Xenopus

Foxi2 和 Sox3 是控制非洲爪蟾外胚层生殖层分化的关键转录调控因子。

Hendrickson, Clark L; Blitz, Ira L; Hussein, Amina; Paraiso, Kitt D; Cho, Jin S; Klymkowsky, Michael W; Kofron, Matthew J; Cho, Ken W Y

Impact of maternal compensation on developmental phenotypes in a zebrafish model of severe congenital muscular dystrophy

母体补偿对斑马鱼严重先天性肌营养不良模型发育表型的影响

Flannery, Kyle P; Mowla, Shorbon; Battula, Namarata; Clark, L Rose; Liu, Deze; Oliveira, Callista D; Venkatesan, Cynthia; Simhon, Lillian M; Karas, Brittany F; Terez, Kristin R; Burbano-Lombana, Daniel; Manzini, M Chiara

Foxh1 is a locus-specific PRC2 recruiter governing germ layer silencing.

Foxh1 是一个位点特异性的 PRC2 招募因子,控制着胚层沉默。

Cho Jin, Hendrickson Clark L, Mar Nathan, Blitz Ira L, Fish Margaret, Wang Wenqi, Cho Ken W Y

Foxi2 and Sox3 are master regulators controlling ectoderm germ layer specification.

Foxi2 和 Sox3 是控制外胚层胚层分化的主调控因子

Hendrickson Clark L, Blitz Ira L, Hussein Amina, Paraiso Kitt D, Cho Jin, Klymkowsky Michael W, Kofron Matthew J, Cho Ken W Y

Loss of miR-9-2 Causes Cerebral Hemorrhage and Hydrocephalus by Widespread Disruption of Cell-Type-Specific Neurodevelopmental Gene Networks.

miR-9-2 的缺失通过广泛破坏细胞类型特异性神经发育基因网络导致脑出血和脑积水

Fregoso S P, Atapattu M, Callies L K, Monet D, Leonardson A, Clark L, Xu S, Cherry T J

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

一项 I 期研究,旨在评估 PF-06939999(PRMT5 抑制剂)在具有高发剪接因子基因突变的特定晚期或转移性肿瘤患者中的安全性、药代动力学和药效学。

Rodon, J; Rodriguez, E; Maitland, M L; Tsai, F Y-C; Socinski, M A; Berlin, J D; Thomas, J S; Al Baghdadi, T; Wang, I-M; Guo, C; Golmakani, M; Clark, L N; Gazdoiu, M; Li, M; Tolcher, A W

The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants

事件发生的房间:临床医生对向研究参与者反馈阿尔茨海默病临床前生物标志物结果的反思

Erickson, C M; Chin, N A; Ketchum, F B; Eveler, M L; Conway, C E; Coughlin, D M; Clark, L R

Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure

阿尔茨海默病生物标志物沟通:认知功能正常的成年人在淀粉样蛋白检测结果披露期间的担忧和理解

Ketchum, F B; Erickson, C M; Basche, K E; Chin, N A; Eveler, M L; Conway, C E; Coughlin, D M; Clark, L R